Set as preferred source
Insights from EY Pharma’s new architecture report.
The pharmaceutical industry is not simply evolving—it is being re-architected.
For decades, the model was predictable: invest in discovery, validate through clinical trials, scale manufacturing, and capture value at launch. That sequence is breaking down. Today, the constraint is no longer scientific capability. It is the ability to execute—reliably, at scale, and under increasing regulatory and geopolitical pressure.
What is emerging instead is a platform-driven system where discovery, data, manufacturing, and supply chains operate as a single integrated architecture. The implications are structural: capital is concentrating, competitive boundaries are shifting, and regions once defined by cost are repositioning as execution hubs.
The core shift: from discovery advantage to execution advantage
The industry’s center of gravity is moving.
Biologics, cell therapies, and RNA-based treatments now dominate high-value pipelines. Biologics already account for ~54% of global prescription revenue (2025) and are projected to approach ~60% by 2028, while cell and gene therapies are expanding at ~35% CAGR. These therapies are not just scientifically complex—they are operationally fragile.
This changes the economics of innovation.
Previously, value was created at the point of discovery. Today, value is realized only if a therapy can move from lab to patient without breakdowns in manufacturing, data, or supply. The failure mode has shifted accordingly: promising drugs no longer fail because they don’t work—they fail because they cannot be scaled or delivered efficiently.
This is why execution—not discovery—has become the defining constraint.
AI moves from tool to infrastructure
AI has been discussed in pharma for years. What has changed is its role.
It is no longer an optimization layer. It is becoming the backbone of the entire development process.
The emerging model is a six-layer architecture:
- Intelligence — data synthesis and hypothesis generation
- Design — molecule and protein engineering
- Simulation — virtual testing before lab work
- Execution — automated experimentation
- Evidence — clinical and real-world data integration
- Regulatory — traceability and approval readiness
This architecture compresses timelines and reduces uncertainty—but more importantly, it transforms how decisions are made. Instead of sequential stages, development becomes a continuous, data-driven loop.
Early signals are already visible: AI-driven workflows are compressing discovery timelines that historically took 5–6 years, with some AI-originated candidates reaching clinical stages in ~12–18 months.
A critical extension of this is the use of digital twins in clinical development. These “narrow twins” simulate trial outcomes—including dropout rates (~20% scenarios), endpoint sensitivity, and patient response—before enrollment begins. The result is smaller, faster, and more targeted trials.
The implication is clear: speed is no longer about moving faster through stages. It is about making better decisions earlier.
The regulatory reset: from experimental to operational
There is a growing misconception that AI adoption in pharma is limited by regulation. The reality is more precise.
Regulators are not slowing adoption—they are redefining the threshold for it.
AI is acceptable only when it is:
- Validated for a defined context of use
- Auditable and reproducible
- Embedded within governed systems
In other words, the bar is operational, not experimental.
This has two consequences. First, AI investments that remain in pilot mode will not translate into approvals. Second, companies that build compliant, auditable systems will gain a structural advantage in speed-to-market.
Parallel to this, intellectual property frameworks are adapting. New guidelines now allow patent protection for AI-generated drug candidates—provided they demonstrate a clear technical effect. This introduces legal clarity around ownership and valuation, turning automated discovery into defensible capital.
Manufacturing becomes strategic infrastructure
Manufacturing is no longer a downstream function. It is part of innovation itself.
As therapies become more complex, manufacturing constraints are moving upstream—shaping decisions at the earliest stages of development. This is particularly evident in biologics and advanced therapies, where production conditions directly affect efficacy and safety.
At the same time, the manufacturing model is being rebuilt:
- Continuous flow chemistry can reduce reaction times from hours to minutes
- Modular systems enable multi-product facilities without full redesign
- Real-time quality systems reduce batch failure and release delays
A quieter but equally important shift is happening in chemistry. Biocatalysis and synthetic biology are replacing traditional methods, enabling cleaner, more efficient production while reducing dependence on complex supply chains.
This is not just an ESG story. It is a resilience strategy. Companies that can produce critical inputs more efficiently—and closer to demand—reduce exposure to geopolitical disruption.
The supply chain becomes a design variable
Recent disruptions have exposed a structural vulnerability: pharmaceutical supply chains are optimized for efficiency, not resilience.
That model is no longer sufficient.
Advanced therapies depend on highly specialized inputs—vectors, enzymes, single-use components—often sourced from a limited number of suppliers. Any disruption can delay development timelines materially.
As a result, supply planning is moving upstream. It is now embedded in development decisions rather than treated as a downstream optimization problem.
This includes:
- Diversifying suppliers early in development
- Localizing critical inputs where possible
- Aligning manufacturing and logistics strategies from the outset
Supply chain resilience is no longer a corrective measure. It is a design requirement.
A quiet shift in operating models
Another structural change is unfolding beneath the surface.
For years, the industry moved toward outsourcing—leveraging CROs and CDMOs to reduce costs and increase flexibility. That model is now being rebalanced.
There is a clear shift toward hybrid and insourced approaches.
The driver is not cost. It is control.
Data, models, and decision systems have become strategic assets. Relying on external partners for core execution introduces opacity—limiting visibility, slowing decisions, and creating dependency.
The emerging model keeps critical capabilities in-house while selectively externalizing execution. This restores control over data flows and enables faster, more transparent decision-making.
The geopolitical layer: India’s repositioning
Geography is becoming a competitive factor again.
India, long positioned as a cost-efficient manufacturing base, is moving up the value chain. It now combines several structural advantages:
- A workforce of ~900,000+ professionals across pharma and adjacent sectors
- A growing network of 1,000+ accredited clinical trial sites
- Strong legacy in generics, now expanding into biologics and advanced modalities
Policy is reinforcing this shift. The INR 10,000 crore SHAKTI program is accelerating investments in clinical infrastructure, regulatory science, and biomanufacturing capabilities.
The opportunity is not incremental. It is structural.
If these capabilities are effectively integrated, India transitions from being a supplier to becoming an execution layer for global pharma—connecting discovery, development, and manufacturing within a single system.
The constraint is coherence. Fragmentation across institutions still limits system-level efficiency. But the direction is clear.
What this means
The industry is entering a phase where isolated excellence is no longer enough.
- Discovery without manufacturability fails
- AI without governance stalls
- Scale without resilience breaks
The competitive advantage is shifting toward those who can integrate these elements into a coherent system.
This changes how value is created:
- From breakthroughs to execution reliability
- From products to platforms
- From speed to decision quality
The result is a quieter but more consequential transformation. Pharma is not just innovating faster—it is becoming structurally different.
And in that structure, the winners are already becoming visible.
